ABT Quote, Financials, Valuation and Earnings

DexCom has a net margin of 84.1% compared to Abbott Laboratories's net margin of 13.62%. Abbott Laboratories's return on equity of 32.63% beat DexCom's return on equity of 26.6%.

Abbott Laboratories has a consensus price target of $136.26, signalling upside risk potential of 4.91%. On the other hand DexCom has an analysts' consensus of $101.79 which suggests that it could grow by 48.64%. Given that DexCom has higher upside potential than Abbott Laboratories, analysts believe DexCom is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.696, which suggesting that the stock is 30.418% less volatile than S&P 500. In comparison DexCom has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.527%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.73%. DexCom offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. DexCom pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11B, which are larger than DexCom quarterly revenues of $1.1B. Abbott Laboratories's net income of $9.2B is higher than DexCom's net income of $151.7M. Notably, Abbott Laboratories's price-to-earnings ratio is 16.98x while DexCom's PE ratio is 47.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.41x versus 7.01x for DexCom. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 84.1% compared to Abbott Laboratories's net margin of 28.41%. Abbott Laboratories's return on equity of 32.63% beat Intuitive Surgical's return on equity of 15.6%.

Abbott Laboratories has a consensus price target of $136.26, signalling upside risk potential of 4.91%. On the other hand Intuitive Surgical has an analysts' consensus of $632.53 which suggests that it could grow by 32.67%. Given that Intuitive Surgical has higher upside potential than Abbott Laboratories, analysts believe Intuitive Surgical is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.696, which suggesting that the stock is 30.418% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.616%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.73%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11B, which are larger than Intuitive Surgical quarterly revenues of $2.4B. Abbott Laboratories's net income of $9.2B is higher than Intuitive Surgical's net income of $685.7M. Notably, Abbott Laboratories's price-to-earnings ratio is 16.98x while Intuitive Surgical's PE ratio is 74.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.41x versus 20.66x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 84.1% compared to Abbott Laboratories's net margin of 15.24%. Abbott Laboratories's return on equity of 32.63% beat Johnson & Johnson's return on equity of 19.98%.

Abbott Laboratories has a consensus price target of $136.26, signalling upside risk potential of 4.91%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.73%. Given that Abbott Laboratories has higher upside potential than Johnson & Johnson, analysts believe Abbott Laboratories is more attractive than Johnson & Johnson.

Abbott Laboratories has a beta of 0.696, which suggesting that the stock is 30.418% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.73%. Johnson & Johnson offers a yield of 3.04% to investors and pays a quarterly dividend of $1.24 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Abbott Laboratories's net income of $9.2B is higher than Johnson & Johnson's net income of $3.4B. Notably, Abbott Laboratories's price-to-earnings ratio is 16.98x while Johnson & Johnson's PE ratio is 28.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.41x versus 4.45x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 84.1% compared to Abbott Laboratories's net margin of 32.59%. Abbott Laboratories's return on equity of 32.63% beat Eli Lilly and's return on equity of 80.24%.

Abbott Laboratories has a consensus price target of $136.26, signalling upside risk potential of 4.91%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 25.57%. Given that Eli Lilly and has higher upside potential than Abbott Laboratories, analysts believe Eli Lilly and is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.696, which suggesting that the stock is 30.418% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.73%. Eli Lilly and offers a yield of 0.67% to investors and pays a quarterly dividend of $1.50 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Abbott Laboratories's net income of $9.2B is higher than Eli Lilly and's net income of $4.4B. Notably, Abbott Laboratories's price-to-earnings ratio is 16.98x while Eli Lilly and's PE ratio is 68.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.41x versus 16.09x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.